Table 1.
Patient characteristics.
| Characteristic | IC + CRT group (n = 55), % | CRT group (n = 55), % |
|---|---|---|
| Age (years) | ||
| Median (IQR) | 57 (52–62) | 60 (54–65) |
| ≤58 | 31 (56.4) | 25 (45.5) |
| >58 | 24 (43.6) | 30 (54.5) |
| Sex | ||
| Male | 39 (70.9) | 43 (78.2) |
| Female | 16 (29.1) | 12 (21.8) |
| Smoking history | ||
| Yes | 40 (72.7) | 41 (74.5) |
| No | 15 (27.3) | 14 (25.5) |
| Alcohol history | ||
| Yes | 32 (58.2) | 36 (65.5) |
| No | 23 (41.8) | 19 (34.5) |
| Weight loss within 3 months | ||
| <10% | 44 (80.0) | 43 (78.2) |
| ≥10% | 11 (20.0) | 12 (21.8) |
| BMI (kg/m2) | ||
| Median (IQR) | 21.6 (19.9–23.3) | 20.3 (18.6–22.0) |
| ≤18.5 | 5 (9.1) | 12 (21.8) |
| >18.5 | 50 (90.9) | 43 (78.2) |
| ECOG performance status | ||
| 0 | 28 (50.9) | 21 (38.2) |
| 1–2 | 27 (49.1) | 34 (61.8) |
| Histologic grade | ||
| Gx/G1/G2 | 47 (85.5) | 49 (89.1) |
| G3 | 8 (14.5) | 6 (10.9) |
| Tumor location | ||
| Upper | 32 (58.2) | 26 (47.3) |
| Middle | 20 (36.4) | 23 (41.8) |
| Distal | 3 (5.5) | 6 (10.9) |
| Primary tumor length (cm) | ||
| Median (IQR) | 5 (4–7) | 5 (4–7) |
| ≤5 | 23 (41.8) | 27 (49.1) |
| >5 | 32 (58.2) | 28 (50.9) |
| Clinical T stage | ||
| T1–2 | 16 (29.1) | 15 (27.3) |
| T3–4 | 39 (70.9) | 40 (72.7) |
| Clinical N stage | ||
| N0 | 7 (12.7) | 9 (16.4) |
| N1 | 48 (87.3) | 46 (83.6) |
| Clinical M stage | ||
| M0 | 40 (72.7) | 36 (65.5) |
| M1a | 15 (27.3) | 19 (34.5) |
| Clinical TNM stage | ||
| IIA | 7 (12.7) | 8 (14.5) |
| IIB | 8 (14.5) | 9 (16.4) |
| III | 25 (45.5) | 19 (34.5) |
| IVA | 15 (27.3) | 19 (34.5) |
| Reason for no surgery | ||
| Inoperable | 40 (72.7) | 38 (69.1) |
| Surgical contraindication | 9 (16.4) | 11 (20.0) |
| Patient refusal | 6 (10.9) | 5 (9.1) |
| Radiotherapy modality | ||
| 3DCRT | 2 (3.6) | 4 (7.3) |
| IMRT | 53 (96.4) | 51 (92.7) |
IC induction chemotherapy, CRT chemoradiotherapy, IQR interquartile range, BMI body mass index, ECOG Eastern Cooperative Oncology Group, 3DCRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy.